{"id":394594,"date":"2020-12-07T12:03:12","date_gmt":"2020-12-07T17:03:12","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=394594"},"modified":"2020-12-07T12:03:12","modified_gmt":"2020-12-07T17:03:12","slug":"the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\/","title":{"rendered":"The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors"},"content":{"rendered":"

<\/p>\n

The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors<\/b><\/p>\n

LOS ANGELES–(BUSINESS WIRE<\/a>)–The Law Offices of Frank R. Cruz<\/a> is investigating potential claims against the board of directors of Zynerba Pharmaceuticals (\u201cZynerba\u201d or the \u201cCompany\u201d) (NASDAQ: ZYNE<\/a>) concerning whether the board breached its fiduciary duties to shareholders.\n<\/p>\n

\nIf you are a shareholder, click here<\/a> to participate.\n<\/p>\n

\nOn September 18, 2019, Zynerba announced results from its BELIEVE 1 Trial evaluating topical gel Zygel in children and adolescents with Developmental and Epileptic Encephalopathy. While Zynerba asserted that Zygel was well-tolerated, the Company disclosed a 96% rate of treatment emergent adverse events, 60% rate of treatment related adverse events. Zynerba also revealed that, among ten patients who reported serious adverse events, two \u201c(lower respiratory tract infection and status epilepticus) were determined to be possibly related to treatment.\u201d\n<\/p>\n

\nOn this news, Zynerba\u2019s stock price fell $2.46 per share, or 21.77%, to close at $8.84 per share on September 18, 2019.\n<\/p>\n

\nOur investigation concerns whether the Company\u2019s board of directors breached its fiduciary duties to shareholders and\/or grossly mismanaged the Company in connection with the above alleged misconduct.\n<\/p>\n

\nFollow us for updates on Twitter: twitter.com\/FRC_LAW<\/a>.\n<\/p>\n

\nIf you still hold Zynerba shares purchased before August, 2019<\/b> and wish to discuss this matter with us, or have any questions concerning your rights and interests with regards to this matter, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com<\/a>, or visit our website at www.frankcruzlaw.com<\/a>.\u00a0 If you inquire by email please include your mailing address, telephone number and number of shares purchased.\n<\/p>\n

\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201207005328\/en\/<\/a><\/span><\/p>\n

\nThe Law Offices of Frank R. Cruz, Los Angeles
\n
Frank R. Cruz, 310-914-5007
\n
fcruz@frankcruzlaw.com
\n<\/a>
www.frankcruzlaw.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Legal Professional Services<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors LOS ANGELES–(BUSINESS WIRE)–The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Zynerba Pharmaceuticals (\u201cZynerba\u201d or the \u201cCompany\u201d) (NASDAQ: ZYNE) concerning whether the board breached its fiduciary duties to shareholders. If you are a shareholder, click here to participate. On September 18, 2019, Zynerba announced results from its BELIEVE 1 Trial evaluating topical gel Zygel in children and adolescents with Developmental and Epileptic Encephalopathy. While Zynerba asserted that Zygel was well-tolerated, the Company disclosed a 96% rate of treatment emergent adverse events, 60% rate of treatment related adverse events. Zynerba also revealed that, among ten patients … <\/p>\n

Continue reading “The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-394594","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nThe Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors LOS ANGELES–(BUSINESS WIRE)–The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Zynerba Pharmaceuticals (\u201cZynerba\u201d or the \u201cCompany\u201d) (NASDAQ: ZYNE) concerning whether the board breached its fiduciary duties to shareholders. If you are a shareholder, click here to participate. On September 18, 2019, Zynerba announced results from its BELIEVE 1 Trial evaluating topical gel Zygel in children and adolescents with Developmental and Epileptic Encephalopathy. While Zynerba asserted that Zygel was well-tolerated, the Company disclosed a 96% rate of treatment emergent adverse events, 60% rate of treatment related adverse events. Zynerba also revealed that, among ten patients … Continue reading "The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-07T17:03:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201207005328r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors\",\"datePublished\":\"2020-12-07T17:03:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\\\/\"},\"wordCount\":362,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201207005328r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\\\/\",\"name\":\"The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201207005328r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2020-12-07T17:03:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201207005328r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201207005328r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\/","og_locale":"en_US","og_type":"article","og_title":"The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors - Market Newsdesk","og_description":"The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors LOS ANGELES–(BUSINESS WIRE)–The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Zynerba Pharmaceuticals (\u201cZynerba\u201d or the \u201cCompany\u201d) (NASDAQ: ZYNE) concerning whether the board breached its fiduciary duties to shareholders. If you are a shareholder, click here to participate. On September 18, 2019, Zynerba announced results from its BELIEVE 1 Trial evaluating topical gel Zygel in children and adolescents with Developmental and Epileptic Encephalopathy. While Zynerba asserted that Zygel was well-tolerated, the Company disclosed a 96% rate of treatment emergent adverse events, 60% rate of treatment related adverse events. Zynerba also revealed that, among ten patients … Continue reading \"The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-07T17:03:12+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201207005328r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors","datePublished":"2020-12-07T17:03:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\/"},"wordCount":362,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201207005328r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\/","name":"The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201207005328r1&sid=flmnd&distro=nx&lang=en","datePublished":"2020-12-07T17:03:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201207005328r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201207005328r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-announces-investigation-of-zynerba-pharmaceuticals-zyne-on-behalf-of-investors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/394594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=394594"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/394594\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=394594"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=394594"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=394594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}